Therapy Insight: Peripheral arterial disease and diabetes - From pathogenesis to treatment guidelines

Nature Clinical Practice Cardiovascular Medicine

Volumn 4, Issue 3, 2007, Pages 151-162

  Mohler, Emile R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; AMFEBUTAMONE; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEZAFIBRATE; CILOSTAZOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MILRINONE; NICOTINIC ACID; NITRIC OXIDE SYNTHASE; PIOGLITAZONE; PLACEBO; PRAVASTATIN; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SIMVASTATIN; SULFONYLUREA; UNINDEXED DRUG; VARENICLINE;

ANTICOAGULATION; ARTERY DISEASE; BLOOD PRESSURE MEASUREMENT; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC FOOT; DIAGNOSTIC TEST; DISEASE ASSOCIATION; DYSLIPIDEMIA; GLYCEMIC CONTROL; HEALTH CARE ORGANIZATION; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; LEG REVASCULARIZATION; LIMB AMPUTATION; LIMB ISCHEMIA; MEDICAL SPECIALIST; META ANALYSIS; MONOTHERAPY; NICOTINE REPLACEMENT THERAPY; PATHOGENESIS; PATIENT CARE; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SMOKING CESSATION; STROKE; SYSTEMATIC REVIEW; THROMBOSIS; TREATMENT PLANNING; UNITED STATES; WALKING;

CHOLESTEROL, LDL; DIABETES COMPLICATIONS; DISEASE PROGRESSION; HUMANS; PERIPHERAL VASCULAR DISEASES; PRACTICE GUIDELINES; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 33847748651     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0823     Document Type: Review

References (66)

1. Hiatt WR (2001) Medical treatment of peripheral arterial disease and claudication. N Engl J Med 344: 1608-1621
2. Kannel WB (1994) Risk factors for atherosclerotic cardiovascular outcomes in different arterial territories. J Cardiovasc Risk 1: 333-339
3. American Diabetes Association (2003) Peripheral arterial disease in people with diabetes. Diabetes Care 26: 3333-3341
4. Hirsch AT et al. (2001) Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286: 1317-1324
5. McAlpine RR et al. (2005) The annual incidence of diabetic complications in a population of patients with Type 1 and Type 2 diabetes. Diabet Med 22: 348-352
6. Weitz JI et al. (1996) Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review. Circulation 94: 3026-3049
7. Khattab AD et al. (2005) Peripheral arterial disease in diabetic patients selected from a primary care setting: Implications for nursing practice. J Vasc Nurs 23: 139-148
8. Hirsch AT et al. (2006) ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Concensus; and Vascular Disease Foundation. Circulation 113: E463-654
9. Dormandy J et al. (1999) Predicting which patients will develop chronic critical leg ischemia. Semin Vasc Surg 12: 138-141
10. Jude EB et al. (2001) Peripheral arterial disease in diabetic and nondiabetic patients: A comparison of severity and outcome. Diabetes Care 24: 1433-1437
11. Centers for Disease Control and Prevention (2005) Mobility limitation among persons aged ≥40 years with and without diagnosed diabetes and lower extremity disease-United States, 1992-2002. Morb Mortal Wkly Rep 54: 1183-1186
12. Lowe GD et al. (1993) Blood viscosity, fibrinogen, and activation of coagulation and leukocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation 87: 1915-1920
13. Eckel RH et al. (2002) Prevention Conference VI: Diabetes and CardiovasculPr Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation 105: E138-143
14. Beckman JA et al. (2002) Diabetes and atherosclerosis: Epidemiology, pathophysiology, and management. JAMA 287: 2570-2581
15. Stevens RJ et al.; United Kingdom Prospective Diabetes Study (UKPDS) Group (2001) The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101: 671-679
16. Turner RC et al. (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316: 823-828
17. Reaven PD et al. (2005) Coronary artery and abdominal aortic calcification are associated with cardiovascular disease in type 2 diabetes. Diabetologia 48: 379-385
18. Creager MA et al. (2003) Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108: 1527-1532
19. Huysmans K et al. (1998) Hypertension and accelerated atherosclerosis in endstage renal disease. J Nephrol 11: 185-195
20. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820
21. Cipollone F et al. (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: Role of glycemic control. Circulation 108: 1070-1077
22. Englyst NA et al. (2003) A novel role for CD36 in VLDL-enhanced platelet activation. Diabetes 52: 1248-1255
23. Nicholson AC et al. (2004) CD36, oxidized LDL and PPAR gamma: pathological interactions in macrophages and atherosclerosis. Vascul Pharmacol 41: 139-146
24. Wild SH et al. (2006) Low ankle-brachial pressure index predicts increased risk of cardiovascular disease independent of the metabolic syndrome and conventional cardiovascular risk factors in the Edinburgh Artery Study. Diabetes Care 29: 637-642
25. Aboyans V et al. (2006) Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 113: 2623-2629
26. Khan NA et al. (2006) Does the clinical examination predict lower extremity peripheral arterial disease? JAMA 295: 536-546
27. Mohler ER III et al. (2004) Utility and barriers to performance of the ankle-brachial index in primary care practice. Vasc Med 9: 253-260
28. Duvall WL et al. (2004) Multi-bed vascular disease and atherothrombosis: scope of the problem. J Thromb Thrombolysis 17: 51-61
29. Haffner SM et al. (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234
30. Ricker PM et al. (2004) Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation 109: 1955-1959
31. Tzoulaki I et al. (2005) C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 112: 976-983
32. Wildman RP et al. (2005) Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol 96: 1579-1583
33. Conroy RM et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 24: 987-1003
34. Law M et al. (1995) An analysis of the effectiveness of interventions intended to help people stop smoking. Arch Intern Med 155: 1933-1941
35. Jorenby DE et al. (1999) A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340: 685-691
36. 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial. JAMA 296: 56-63
37. Gonzales D et al. (2006) Varenicline, an α4 β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296: 47-55
38. Tonstad S et al. (2006) Effect of maintenance therapy with varenicline on smoking cessation: A randomized controlled trial. JAMA 296: 64-71
39. Nathan DM et al. (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353: 2643-2653
40. Stratton IM et al. (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321: 405-412
41. UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865
42. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853
43. Dormandy JA et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet 366: 1279-1289
44. Pyorala K et al. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20: 614-620
45. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 7-22
46. Collins R et al.; Heart Protection Study Collaborative Group (2003) MRC/ BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 361: 2005-2016
47. Mohler ER III et al. (2003) Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108: 1481-1486
48. Haffner SM (2004) Dyslipidemia management in adults with diabetes. Diabetes Care 27 (Suppl 1): S68-S71
49. Graham DJ et al. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292: 2585-2590
50. Keech A et al. (2005) Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet 366: 1849-1861
51. Meade T et al. (2002) Bezafibrate in men with lower extremity arterial disease: Randomised controlled trial. BMJ 325: 1139-1144
52. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317: 703-713
53. Hennekens CH et al. (11996) Adjunctive drug therapy of acute myocardial infarction-evidence from clinical trials. N Engl J Med 335: 1660-1667
54. Yusuf S et al. (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 145-153
55. Bosch J et al. (2005) Long-term effects of ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension. Circulation 112: 1339-1346
56. Chobanian AV et al. (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289: 2560-2572
57. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatellet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324: 71-86
58. CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348: 1329-1339
59. Bhatt DL et al. (2002) Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90: 625-628
60. Clagett GP et al. (2004) Antithrombotic therapy in peripheral arterial occlusive disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 (Suppl 3): S609-S626
61. Peripheral Arterial Diseases Antiplatelet Consensus Group (2003) Antiplatelet therapy in peripheral arterial disease: Consensus statement. Eur J Vasc Endovasc Surg 26: 1-16
62. Gardner AW et al. (1995) Exercise rehabilitation programs for the treatment of claudication pain: A meta-analysis. JAMA 274: 975-980
63. Menard JR et al. (2004) Long-term results of peripheral arterial disease rehabilitation. J Vasc Surg 39: 1186-1192
64. Reilly MP et al. (2001) Cilostazol: Treatment of intermittent claudication. Ann Pharmacother 35: 48-56
65. Regensteiner JG et al. (2002) Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: Meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50: 1939-1946
66. Herman WH et al. (2005) Underdiagnosis of peripheral neuropathy in type 2 diabetes. Diabetes Care 28: 1480-1481